# SRX Global Inc.: financial statements, quarterly

SRXH · NYSE · CIK 1471727 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/srxh.md) · [Financials](/companies/srxh/financials.md) · [Filings](/companies/srxh/filings.md) · [Insiders](/companies/srxh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/srxh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.1](/filings/0001493152-24-045248.md) | [5.7 d](/filings/0001641172-25-001558.md) | [7.9](/filings/0001641172-25-011011.md) | [42.7](/filings/0001493152-25-016260.md) | [11.4](/filings/0001493152-24-045248.md) | [7.2 d](/filings/0001641172-25-001558.md) | [7.2](/filings/0001641172-25-011011.md) | [2.7](/filings/0001493152-26-037793.md) | [3.9 d](/filings/0001493152-25-026452.md) | [2.8](/filings/0001493152-26-006816.md) | [3.4](/filings/0001493152-26-023072.md) | [3.4](/filings/0001493152-26-037793.md) |
| Cost of revenue | $m | [8.7](/filings/0001493152-24-045248.md) | [5.2 d](/filings/0001641172-25-001558.md) | [5.3](/filings/0001641172-25-011011.md) | [33.3](/filings/0001493152-25-016260.md) | [6.9](/filings/0001493152-24-045248.md) | [4.6 d](/filings/0001641172-25-001558.md) | [4.8](/filings/0001641172-25-011011.md) | [2.6](/filings/0001493152-26-037793.md) | [2.4 d](/filings/0001493152-25-026452.md) | [1.8](/filings/0001493152-26-006816.md) | [2.2](/filings/0001493152-26-023072.md) | [2.5](/filings/0001493152-26-037793.md) |
| Gross profit | $m | [4.4](/filings/0001493152-24-045248.md) | [0.5 d](/filings/0001641172-25-001558.md) | [2.6](/filings/0001641172-25-011011.md) | [9.4](/filings/0001493152-25-016260.md) | [4.5](/filings/0001493152-24-045248.md) | [2.6 d](/filings/0001641172-25-001558.md) | [2.4](/filings/0001641172-25-011011.md) | [0.0](/filings/0001493152-26-037793.md) | [1.5 d](/filings/0001493152-25-026452.md) | [1.1](/filings/0001493152-26-006816.md) | [1.3](/filings/0001493152-26-023072.md) | [0.9](/filings/0001493152-26-037793.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [7.1](/filings/0001493152-24-045248.md) | [4.7 d](/filings/0001641172-25-001558.md) | [5.1](/filings/0001641172-25-011011.md) | [10.7](/filings/0001493152-25-016260.md) | [5.6](/filings/0001493152-24-045248.md) | [4.3 d](/filings/0001641172-25-001558.md) | [3.5](/filings/0001641172-25-011011.md) | [8.6](/filings/0001493152-26-037793.md) | [4.3 d](/filings/0001493152-25-026452.md) | [4.8](/filings/0001493152-26-006816.md) | [3.1](/filings/0001493152-26-023072.md) | [4.1](/filings/0001493152-26-037793.md) |
| Operating income | $m | [(2.6)](/filings/0001493152-24-045248.md) | [(12.7) d](/filings/0001641172-25-001558.md) | [(2.5)](/filings/0001641172-25-011011.md) | [(1.3)](/filings/0001493152-25-016260.md) | [(1.1)](/filings/0001493152-24-045248.md) | [(1.6) d](/filings/0001641172-25-001558.md) | [(1.1)](/filings/0001641172-25-011011.md) | [(8.6)](/filings/0001493152-26-037793.md) | [(2.8) d](/filings/0001493152-25-026452.md) | [(3.8)](/filings/0001493152-26-006816.md) | [(1.8)](/filings/0001493152-26-023072.md) | [(3.2)](/filings/0001493152-26-037793.md) |
| Interest expense | $m | not reported | not reported | [0.4](/filings/0001493152-24-020392.md) | [0.2](/filings/0001493152-24-032012.md) | not reported | not reported | not reported | [(0.0)](/filings/0001493152-26-037793.md) | [0.7 d](/filings/0001493152-25-026452.md) | [1.3](/filings/0001493152-26-006816.md) | [1.8](/filings/0001493152-26-023072.md) | [0.6](/filings/0001493152-26-037793.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001641172-25-011011.md) | [0.3](/filings/0001493152-25-016260.md) | [(0.0)](/filings/0001493152-24-045248.md) | [0.0 d](/filings/0001641172-25-001558.md) | [0.0](/filings/0001641172-25-011011.md) | [0.1](/filings/0001493152-25-016260.md) | not reported | [0.0](/filings/0001493152-26-006816.md) | [0.0](/filings/0001493152-26-023072.md) | [0.0 d](/filings/0001493152-26-037793.md) |
| Net income | $m | [(1.6)](/filings/0001493152-24-045248.md) | [(14.7) d](/filings/0001641172-25-001558.md) | [(2.8)](/filings/0001641172-25-011011.md) | [(3.1)](/filings/0001493152-25-016260.md) | [1.5](/filings/0001493152-24-045248.md) | [(4.0)](/filings/0001493152-26-037793.md) | [(10.1)](/filings/0001493152-26-037793.md) | [(15.1)](/filings/0001493152-26-037793.md) | [(15.3) d](/filings/0001493152-25-026452.md) | [(8.6)](/filings/0001493152-26-037793.md) | [(6.4)](/filings/0001493152-26-037793.md) | [(4.1)](/filings/0001493152-26-037793.md) |
| Diluted EPS | $ per share | [(2.30)](/filings/0001493152-24-045248.md) | not reported | [(3.60)](/filings/0001641172-25-011011.md) | [(0.14)](/filings/0001493152-25-016260.md) | [0.73](/filings/0001493152-24-045248.md) | [(0.17)](/filings/0001493152-26-006816.md) | [(0.39)](/filings/0001493152-26-023072.md) | [(44.51)](/filings/0001493152-26-037793.md) | not reported | [(0.26)](/filings/0001493152-26-006816.md) | [(0.02)](/filings/0001493152-26-023072.md) | [(0.36)](/filings/0001493152-26-037793.md) |
| Basic EPS | $ per share | [(2.30)](/filings/0001493152-24-045248.md) | not reported | [(3.60)](/filings/0001641172-25-011011.md) | [(0.14)](/filings/0001493152-25-016260.md) | [0.73](/filings/0001493152-24-045248.md) | [(0.17)](/filings/0001493152-26-006816.md) | [(0.39)](/filings/0001493152-26-023072.md) | [(44.51)](/filings/0001493152-26-037793.md) | not reported | [(0.26)](/filings/0001493152-26-006816.md) | [(0.02)](/filings/0001493152-26-023072.md) | [(0.36)](/filings/0001493152-26-037793.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.8](/filings/0001493152-23-040650.md) | [4.5](/filings/0001641172-25-001558.md) | [3.9](/filings/0001493152-24-020392.md) | [3.3](/filings/0001493152-24-032012.md) | [0.1](/filings/0001493152-25-026452.md) | [3.1](/filings/0001641172-25-011011.md) | [1.1](/filings/0001641172-25-011011.md) | [0.9](/filings/0001493152-25-016260.md) | [1.3](/filings/0001493152-26-037793.md) | [13.1](/filings/0001493152-26-006816.md) | [20.5](/filings/0001493152-26-023072.md) | [35.2](/filings/0001493152-26-037793.md) |
| Current assets | $m | [20.9](/filings/0001493152-23-040650.md) | [16.2](/filings/0001641172-25-001558.md) | [14.6](/filings/0001493152-24-020392.md) | [12.2](/filings/0001493152-24-032012.md) | [13.6](/filings/0001493152-25-026452.md) | [15.0](/filings/0001641172-25-011011.md) | [14.5](/filings/0001641172-25-011011.md) | [24.5](/filings/0001493152-25-016260.md) | [8.1](/filings/0001493152-26-037793.md) | [18.8](/filings/0001493152-26-006816.md) | [43.1](/filings/0001493152-26-023072.md) | [65.2](/filings/0001493152-26-037793.md) |
| Total assets | $m | [31.0](/filings/0001493152-23-040650.md) | [16.7](/filings/0001641172-25-001558.md) | [15.4](/filings/0001493152-24-020392.md) | [13.1](/filings/0001493152-24-032012.md) | [33.8](/filings/0001493152-25-026452.md) | [15.8](/filings/0001641172-25-011011.md) | [15.3](/filings/0001641172-25-011011.md) | [34.0](/filings/0001493152-25-016260.md) | [8.4](/filings/0001493152-26-037793.md) | [27.1](/filings/0001493152-26-006816.md) | [43.4](/filings/0001493152-26-023072.md) | [145](/filings/0001493152-26-037793.md) |
| Current liabilities | $m | [13.2](/filings/0001493152-23-040650.md) | [13.7](/filings/0001641172-25-001558.md) | [14.3](/filings/0001493152-24-020392.md) | [9.1](/filings/0001493152-24-032012.md) | [81.3](/filings/0001493152-25-026452.md) | [7.1](/filings/0001641172-25-011011.md) | [7.3](/filings/0001641172-25-011011.md) | [74.1](/filings/0001493152-25-016260.md) | [3.5](/filings/0001493152-26-037793.md) | [23.5](/filings/0001493152-26-006816.md) | [25.1](/filings/0001493152-26-023072.md) | [2.4](/filings/0001493152-26-037793.md) |
| Total liabilities | $m | [16.0](/filings/0001493152-23-040650.md) | [13.8](/filings/0001641172-25-001558.md) | [14.3](/filings/0001493152-24-020392.md) | [9.1](/filings/0001493152-24-032012.md) | [88.9](/filings/0001493152-25-026452.md) | [7.2](/filings/0001641172-25-011011.md) | [7.3](/filings/0001641172-25-011011.md) | [79.9](/filings/0001493152-25-016260.md) | [8.0](/filings/0001493152-26-037793.md) | [23.5](/filings/0001493152-26-006816.md) | [25.1](/filings/0001493152-26-023072.md) | [2.4](/filings/0001493152-26-037793.md) |
| Long-term debt | $m | [2.7](/filings/0001493152-23-040650.md) | [4.6](/filings/0001641172-25-001558.md) | [5.4](/filings/0001493152-24-020392.md) | not reported | [0.7](/filings/0001493152-25-026452.md) | [2.4](/filings/0001641172-25-011011.md) | not reported | [1.9](/filings/0001493152-25-016260.md) | [0.0](/filings/0001493152-26-037793.md) | not reported | [0.0](/filings/0001493152-26-023072.md) | [0.0](/filings/0001493152-26-037793.md) |
| Current portion of debt | $m | [1.9](/filings/0001493152-23-040650.md) | [4.6](/filings/0001641172-25-001558.md) | [5.2](/filings/0001493152-24-020392.md) | [1.6](/filings/0001493152-24-032012.md) | [31.6](/filings/0001493152-25-026452.md) | [2.4](/filings/0001641172-25-001558.md) | [1.2](/filings/0001641172-25-011011.md) | [24.8](/filings/0001493152-25-016260.md) | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [0.3](/filings/0001493152-23-040650.md) | [0.2](/filings/0001641172-25-001558.md) | [0.0](/filings/0001493152-24-020392.md) | not reported | [3.7](/filings/0001493152-25-026452.md) | not reported | not reported | [4.1](/filings/0001493152-25-016260.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(33.8)](/filings/0001493152-25-026452.md) | [2.9](/filings/0001641172-25-011011.md) | [1.1](/filings/0001641172-25-011011.md) | [(21.7)](/filings/0001493152-25-016260.md) | [(55.1)](/filings/0001493152-26-037793.md) | [(63.7)](/filings/0001493152-26-037793.md) | [(58.7)](/filings/0001493152-26-037793.md) | [(45.9)](/filings/0001493152-26-037793.md) | [0.4](/filings/0001493152-26-037793.md) | [3.5](/filings/0001493152-26-037793.md) | [18.3](/filings/0001493152-26-037793.md) | [143](/filings/0001493152-26-037793.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.3 d](/filings/0001493152-24-045248.md) | [1.0 d](/filings/0001641172-25-001558.md) | [(1.0)](/filings/0001641172-25-011011.md) | [0.0 d](/filings/0001493152-24-032012.md) | [(2.1) d](/filings/0001493152-25-026452.md) | [1.5](/filings/0001493152-26-006816.md) | [0.4](/filings/0001641172-25-011011.md) | [(15.8) d](/filings/0001493152-25-016260.md) | [7.6 d](/filings/0001493152-25-026452.md) | [(2.9)](/filings/0001493152-26-006816.md) | [(6.6) d](/filings/0001493152-26-023072.md) | not reported |
| Capital expenditure | $m | [0.0 d](/filings/0001493152-24-045248.md) | [0.0 d](/filings/0001641172-25-001558.md) | [0.0](/filings/0001641172-25-011011.md) | [0.0 d](/filings/0001493152-24-032012.md) | [0.0 d](/filings/0001493152-24-045248.md) | [0.0 d](/filings/0001641172-25-001558.md) | [0.0](/filings/0001641172-25-011011.md) | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001493152-26-037793.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.7](/filings/0001493152-24-020392.md) | [0.7](/filings/0001493152-24-032012.md) | [0.7](/filings/0001493152-24-045248.md) | [0.8](/filings/0001641172-25-011011.md) | [21.9](/filings/0001493152-25-016260.md) | [2.1](/filings/0001493152-24-045248.md) | [23.6](/filings/0001493152-26-006816.md) | [25.8](/filings/0001493152-26-023072.md) | [0.3](/filings/0001493152-26-037793.md) | [33.7](/filings/0001493152-26-006816.md) | [299](/filings/0001493152-26-023072.md) | [11.4](/filings/0001493152-26-037793.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,265,391 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037793.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.